JP2023506410A - ラパマイシン類似体及びその使用 - Google Patents

ラパマイシン類似体及びその使用 Download PDF

Info

Publication number
JP2023506410A
JP2023506410A JP2022534146A JP2022534146A JP2023506410A JP 2023506410 A JP2023506410 A JP 2023506410A JP 2022534146 A JP2022534146 A JP 2022534146A JP 2022534146 A JP2022534146 A JP 2022534146A JP 2023506410 A JP2023506410 A JP 2023506410A
Authority
JP
Japan
Prior art keywords
compounds
compound
nitrogen
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506410A5 (https=
Inventor
オニール，デビッド，ジョン
サイア，エディン
カン，ソン，ウー，アントニー
Original Assignee
アナクリア セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナクリア セラピューティクス， インコーポレイテッド filed Critical アナクリア セラピューティクス， インコーポレイテッド
Publication of JP2023506410A publication Critical patent/JP2023506410A/ja
Publication of JP2023506410A5 publication Critical patent/JP2023506410A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022534146A 2019-12-05 2020-12-04 ラパマイシン類似体及びその使用 Pending JP2023506410A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944166P 2019-12-05 2019-12-05
US62/944,166 2019-12-05
PCT/US2020/063351 WO2021113665A1 (en) 2019-12-05 2020-12-04 Rapamycin analogs and uses thereof

Publications (2)

Publication Number Publication Date
JP2023506410A true JP2023506410A (ja) 2023-02-16
JP2023506410A5 JP2023506410A5 (https=) 2023-12-12

Family

ID=76222025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534146A Pending JP2023506410A (ja) 2019-12-05 2020-12-04 ラパマイシン類似体及びその使用

Country Status (12)

Country Link
US (3) US11819476B2 (https=)
EP (1) EP4069223A4 (https=)
JP (1) JP2023506410A (https=)
KR (1) KR20220128345A (https=)
CN (1) CN115209897A (https=)
AU (1) AU2020397938A1 (https=)
BR (1) BR112022010754A2 (https=)
CA (1) CA3163680A1 (https=)
IL (1) IL293549A (https=)
MX (1) MX2022006807A (https=)
TW (1) TW202134234A (https=)
WO (1) WO2021113665A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530778A (ja) * 2020-03-27 2023-07-19 エオビアン ファーマシューティカルズ， インコーポレイテッド Ｍｔｏｒｃ１モジュレーターおよびその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
AU2020397938A1 (en) * 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN121426814A (zh) * 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
US20220267352A1 (en) * 2021-01-22 2022-08-25 Anakuria Therapeutics, Inc. Rapamycin analogs and uses thereof
CN116917294A (zh) * 2021-01-22 2023-10-20 詹森药业有限公司 雷帕霉素类似物及其用途
CN114539203A (zh) * 2022-03-10 2022-05-27 李科 一种低成本碳酸亚乙烯酯的合成方法
US20250334588A1 (en) * 2022-04-09 2025-10-30 The Brigham And Women's Hospital, Inc. Treating tuberous sclerosis complex-associated diseases
CN115097046B (zh) * 2022-07-07 2023-09-26 国药集团川抗制药有限公司 一种分离雷帕霉素及其杂质的方法
CN116642992A (zh) * 2023-04-27 2023-08-25 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种人体血浆抗肝癌哺乳动物雷帕霉素靶蛋白抑制剂串联质谱检测试剂盒
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509246A (ja) * 1992-07-17 1995-10-12 スミスクライン・ビーチャム・コーポレイション ラパマイシン誘導体
JPH0948737A (ja) * 1995-05-26 1997-02-18 Sando Yakuhin Kk サイクロデキストリン組成物
JPH09506604A (ja) * 1993-12-17 1997-06-30 サンド・リミテッド 免疫抑制剤として有用なラパマイシン誘導体
WO2001014387A1 (en) * 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
JP2002508971A (ja) * 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002514165A (ja) * 1996-07-12 2002-05-14 アリアド・ファーマシューティカルズ・インコーポレイテッド 病原性真菌感染の治療または予防材料および方法
US20050131008A1 (en) * 2003-11-12 2005-06-16 Sun Biomedical, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US20060018955A1 (en) * 2002-06-26 2006-01-26 Deroyal Industries, Inc. Method for preparing medical dressings
JP2009513522A (ja) * 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト 骨減少の処置のための、ラパマイシンおよびラパマイシン誘導体の使用
WO2017044720A1 (en) * 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2018204416A1 (en) * 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
JP2021528396A (ja) * 2018-06-15 2021-10-21 ナビター ファーマシューティカルズ， インコーポレイテッド ラパマイシン類似体およびその使用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
WO1994025072A1 (en) 1993-04-23 1994-11-10 American Home Products Corporation Rapamycin conjugates and antibodies
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
AU735648B2 (en) * 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP0927182A2 (en) 1996-09-09 1999-07-07 American Home Products Corporation Alkylated rapamycin derivatives
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
EA016945B1 (ru) 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
ES2365869T3 (es) 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070203168A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
CL2007000995A1 (es) 2006-04-11 2008-06-27 Smithkline Beecham Corp Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras.
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
WO2008014434A2 (en) 2006-07-28 2008-01-31 Caracal, Inc. Crystal growth method and reactor design
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US20090253733A1 (en) 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
LT2294072T (lt) 2008-05-23 2017-06-12 Wyeth Llc Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai
MX2010014230A (es) 2008-06-20 2011-03-29 Astrazeneca Ab Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010114484A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
MX2013000617A (es) 2010-07-16 2013-06-13 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US8808256B2 (en) 2012-01-16 2014-08-19 Johnson & Johnson Vision Care, Inc. Eye drug delivery system
US9072678B2 (en) 2013-03-14 2015-07-07 Pathak Holdings Llc Methods for local drug delivery by microinjection
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
US20160279108A1 (en) 2015-02-24 2016-09-29 University Of Kansas Targeted mtor inhibitors
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
HRP20250197T1 (hr) 2018-12-18 2025-04-11 Novartis Ag Derivati rapamicina
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
US20220202787A1 (en) 2019-03-26 2022-06-30 Novartis Ag Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof
AU2020397938A1 (en) * 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509246A (ja) * 1992-07-17 1995-10-12 スミスクライン・ビーチャム・コーポレイション ラパマイシン誘導体
JPH09506604A (ja) * 1993-12-17 1997-06-30 サンド・リミテッド 免疫抑制剤として有用なラパマイシン誘導体
JPH0948737A (ja) * 1995-05-26 1997-02-18 Sando Yakuhin Kk サイクロデキストリン組成物
JP2002514165A (ja) * 1996-07-12 2002-05-14 アリアド・ファーマシューティカルズ・インコーポレイテッド 病原性真菌感染の治療または予防材料および方法
JP2002508971A (ja) * 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
WO2001014387A1 (en) * 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20060018955A1 (en) * 2002-06-26 2006-01-26 Deroyal Industries, Inc. Method for preparing medical dressings
JP2009513522A (ja) * 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト 骨減少の処置のための、ラパマイシンおよびラパマイシン誘導体の使用
US20050131008A1 (en) * 2003-11-12 2005-06-16 Sun Biomedical, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
WO2017044720A1 (en) * 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2018204416A1 (en) * 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
JP2021528396A (ja) * 2018-06-15 2021-10-21 ナビター ファーマシューティカルズ， インコーポレイテッド ラパマイシン類似体およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAYLE, J. HENRI ET AL.: "Rapamycin analogs with differential binding specificity permit orthogonal control of protein activit", CHEMISTRY & BIOLOGY, vol. Vol.13(1), JPN6024048720, 2006, pages 99 - 107, ISSN: 0005636544 *
LUENGO, JUAN I. ET AL.,: "Manipulation of the Rapamycin Effector Domain. Selective Nucleophilic Substitution of the C7 Methoxy", JOURNAL OF ORGANIC CHEMISTRY, vol. Vol.59(22), JPN6024048721, 1994, pages 6512 - 6513, ISSN: 0005636543 *
LUENGO, JUAN I. ET AL.: "Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the", CHEMISTRY & BIOLOGY, vol. Vol.2(7), JPN6024048719, 1995, pages 471 - 481, ISSN: 0005474953 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530778A (ja) * 2020-03-27 2023-07-19 エオビアン ファーマシューティカルズ， インコーポレイテッド Ｍｔｏｒｃ１モジュレーターおよびその使用
JP7606591B2 (ja) 2020-03-27 2024-12-25 エオビアン ファーマシューティカルズ， インコーポレイテッド Ｍｔｏｒｃ１モジュレーターおよびその使用

Also Published As

Publication number Publication date
WO2021113665A1 (en) 2021-06-10
TW202134234A (zh) 2021-09-16
US20240139164A1 (en) 2024-05-02
MX2022006807A (es) 2022-09-12
US20240131012A1 (en) 2024-04-25
KR20220128345A (ko) 2022-09-20
EP4069223A1 (en) 2022-10-12
EP4069223A4 (en) 2023-12-20
US20210186935A1 (en) 2021-06-24
IL293549A (en) 2022-08-01
US11819476B2 (en) 2023-11-21
BR112022010754A2 (pt) 2022-08-23
CN115209897A (zh) 2022-10-18
AU2020397938A1 (en) 2022-06-23
CA3163680A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US20240131012A1 (en) Rapamycin analogs and uses thereof
JP7727700B2 (ja) ラパマイシン類似体およびその使用
US20220267352A1 (en) Rapamycin analogs and uses thereof
HK40105219A (en) Rapamycin analogs and uses thereof
HK40082250A (en) Rapamycin analogs and uses thereof
CN116917294A (zh) 雷帕霉素类似物及其用途
EA049308B1 (ru) Аналоги рапамицина и их применения
EA045993B1 (ru) Аналоги рапамицина и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708